Feldmeyer Laurence, Hudgens Courtney W, Ray-Lyons Genevieve, Nagarajan Priyadharsini, Aung Phyu P, Curry Jonathan L, Torres-Cabala Carlos A, Mino Barbara, Rodriguez-Canales Jaime, Reuben Alexandre, Chen Pei-Ling, Ko Jennifer S, Billings Steven D, Bassett Roland L, Wistuba Ignacio I, Cooper Zachary A, Prieto Victor G, Wargo Jennifer A, Tetzlaff Michael T
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res. 2016 Nov 15;22(22):5553-5563. doi: 10.1158/1078-0432.CCR-16-0392. Epub 2016 May 10.
Merkel cell carcinoma (MCC) is an aggressive cancer with frequent metastasis and death with few effective therapies. Because programmed death ligand-1 (PD-L1) is frequently expressed in MCC, immune checkpoint blockade has been leveraged as treatment for metastatic disease. There is therefore a critical need to understand the relationships between MCPyV status, immune profiles, and patient outcomes.
IHC for CD3, CD8, PD-1, PD-L1, and MCPyV T-antigen (to determine MCPyV status) was performed on 62 primary MCCs with annotated clinical outcomes. Automated image analysis quantified immune cell density (positive cells/mm) at discrete geographic locations (tumor periphery, center, and hotspot). T-cell receptor sequencing (TCRseq) was performed in a subset of MCCs.
No histopathologic variable associated with overall survival (OS) or disease-specific survival (DSS), whereas higher CD3 (P = 0.004) and CD8 (P = 0.037) T-cell density at the tumor periphery associated with improved OS. Higher CD8 T-cell density at the tumor periphery associated with improved DSS (P = 0.049). Stratifying MCCs according to MCPyV status, higher CD3 (P = 0.026) and CD8 (P = 0.015) T-cell density at the tumor periphery associated with improved OS for MCPyV but not MCPyV MCC. TCRseq revealed clonal overlap among MCPyV samples, suggesting an antigen-specific response against a unifying antigen.
These findings establish the tumor-associated immune infiltrate at the tumor periphery as a robust prognostic indicator in MCC and provide a mechanistic rationale to further examine whether the immune infiltrate at the tumor periphery is relevant as a biomarker for response in ongoing and future checkpoint inhibitor trials in MCC. Clin Cancer Res; 22(22); 5553-63. ©2016 AACR.
默克尔细胞癌(MCC)是一种侵袭性癌症,常发生转移且死亡率高,有效治疗方法很少。由于程序性死亡配体1(PD-L1)在MCC中经常表达,免疫检查点阻断已被用作转移性疾病的治疗方法。因此,迫切需要了解MCPyV状态、免疫谱和患者预后之间的关系。
对62例有注释临床结果的原发性MCC进行CD3、CD8、PD-1、PD-L1和MCPyV T抗原的免疫组化(以确定MCPyV状态)。自动图像分析量化了离散地理位置(肿瘤周边、中心和热点)的免疫细胞密度(阳性细胞/mm)。在一部分MCC中进行了T细胞受体测序(TCRseq)。
没有组织病理学变量与总生存期(OS)或疾病特异性生存期(DSS)相关,而肿瘤周边较高的CD3(P = 0.004)和CD8(P = 0.037)T细胞密度与OS改善相关。肿瘤周边较高的CD8 T细胞密度与DSS改善相关(P = 0.049)。根据MCPyV状态对MCC进行分层,肿瘤周边较高的CD3(P = 0.026)和CD8(P = 0.015)T细胞密度与MCPyV阳性而非MCPyV阴性MCC的OS改善相关。TCRseq揭示了MCPyV样本之间的克隆重叠,表明针对统一抗原的抗原特异性反应。
这些发现确立了肿瘤周边的肿瘤相关免疫浸润作为MCC中一个强大的预后指标,并提供了一个机制依据,以进一步研究肿瘤周边的免疫浸润是否作为MCC正在进行和未来的检查点抑制剂试验中反应的生物标志物相关。临床癌症研究;22(22);5553 - 63。©2016美国癌症研究协会。